Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASH 2018 /
CD19-directed CAR T-cell therapy for patients with relapsed B-cell acute lymphocytic leukaemia

1st - 4th Dec 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 01.12.18
Views: 480

Dr Shannon Maude - Children’s Hospital of Philadelphia, Philadelphia, USA

Dr Shannon Maude gives a press conference at ASH 2018 about whether adding another immunotherapy agent to the CAR T-cell therapy regimen to prevent the immune system’s natural response, could extend treatment response and improve outcomes for children with relapsed B-ALL.

Watch her interview with ecancer here.

Read the article about this work here.


Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation